Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EACR 2016 /
'Rewiring' tumour susceptibility

9th - 12th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.07.16
Views: 1418

Dr Michael Yaffe - MIT, Cambridge, USA

Dr Yaffe speaks with ecancertv at EACR 2016 about the 'rewiring' of tumours to increase drug sensitivity.

By pre-treating tumours with an EGFR inhibitor to trigger this rewiring response, he reports increased vulnerability to cytotoxic treatments.

Dr Yaffe compares this 'dynamic' response in tumours to the 'static' pathways which can lead to oncogenesis, and may be a valuable, non-host target. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation